Nutex Health price target raised to $75 from $50 at Maxim

Maxim raised the firm’s price target on Nutex Health (NUTX) to $75 from $50 and keeps a Buy rating on the shares. The company announced it reached its goal of submitting between 60%-70% of its billable visits to arbitration through the Independent Dispute Resolution process per month, and achieved an arbitration success rate of about 80% during Q4, the analyst tells investors in a research note. The firm adds it is also pleased with Nutex’s execution of its business strategy, including its recent de novo hospital opening, marking its initial entry into Florida – a market offering strong demand for ER services and a favorable regulatory environment.